#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

In this in-depth episode of The Peter Attia Drive, Dr. Peter Attia dismantles the current U.S. Preventive Services Task Force (USPSTF) guidelines against prostate-specific antigen (PSA) screening, arguing they are outdated and have contributed to a rising tide of advanced and metastatic prostate cancer diagnoses. He explains that while PSA testing was initially criticized for causing overdiagnosis and overtreatment, modern tools like PSA velocity, PSA density, contrast-free biparametric MRI, transperineal biopsy, and active surveillance have dramatically improved early detection while minimizing harm. Attia highlights that the cornerstone study used to justify the USPSTF's stance—the PLCO trial—was fatally compromised by widespread screening in the control group, rendering its conclusions invalid. He emphasizes that when properly analyzed, the same data show PSA screening reduces prostate cancer mortality by 27–32%. A critical and underappreciated issue he raises is the impact of finasteride, a common hair loss drug that suppresses PSA by up to 50%, potentially masking cancer if clinicians don’t adjust for it. He urges patients on finasteride to inform their doctors and for physicians to double (or more) PSA values to avoid missing aggressive cancers. Attia concludes with cautious optimism: with the right tools and awareness, prostate cancer deaths could be nearly eradicated.